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OBJECTIVE— A recent randomized trial compared prandial insulin aspart (IAsp) with hu-
man insulin in type 1 diabetic pregnancy. The aim of this exploratory analysis was to investigate
the incidence of severe hypoglycemia during pregnancy and compare women enrolled precon-
ception with women enrolled during early pregnancy.
RESEARCH DESIGN ANDMETHODS— IAsp administered immediately before each
meal was compared with human insulin administered 30 min before each meal in 99 subjects (44
to IAsp and 55 to human insulin) randomly assigned preconception and in 223 subjects (113 for
IAsp and 110 for human insulin) randomly assigned in early pregnancy (10 weeks). NPH
insulin was the basal insulin. Severe hypoglycemia (requiring third-party assistance) was re-
corded prospectively preconception (where possible), during pregnancy, and postpartum. Rel-
ative risk (RR) of severe hypoglycemia was evaluated with a gamma frailty model.
RESULTS— Of the patients, 23% experienced severe hypoglycemia during pregnancy with
the peak incidence in early pregnancy. In the first half of pregnancy, the RR of severe hypogly-
cemia in women randomly assigned in early pregnancy/preconception was 1.70 (95% CI 0.91–
3.18, P 0.097); the RR in the second half of pregnancy was 1.35 (0.38–4.77, P 0.640). In
women randomly assigned preconception, severe hypoglycemia rates occurring before and
during the first and second halves of pregnancy and postpartum for IAsp versus human insulin
were 0.9 versus 2.4, 0.9 versus 2.4, 0.3 versus 1.2, and 0.2 versus 2.2 episodes per patient per
year, respectively (NS).
CONCLUSIONS— These data suggest that initiation of insulin analog treatment precon-
ception rather than during early pregnancy may result in a lower risk of severe hypoglycemia in
women with type 1 diabetes.
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S evere hypoglycemia is common inpregnant women with type 1 diabe-tes, with observed rates up to 15
times those reported by the Diabetes Con-
trol and Complications Trial (1), and se-
vere hypoglycemia occurs in 19–44% of
patients treated with intensive insulin
therapy during pregnancy (2). The risk of
experiencing a severe event is usually
highest in early pregnancy, particularly
during the first trimester (3–5).
The risk factors that predict severe
hypoglycemic episodes during pregnancy
include duration of diabetes, a history of
previous severe episodes (recurrent
events), hypoglycemic unawareness, a
change in insulin treatment (such as reg-
imen or dosing) or a high insulin dose,
and A1C 6.5% (4,6,7). However, be-
cause normoglycemia is universally rec-
ommended in diabetic pregnancy (8,9),
with A1C levels between 4.0 and 6.0%
advocated to optimize pregnancy out-
come (10,11), minimizing the risk of se-
vere hypoglycemia is a major challenge to
those caring for pregnant women with
type 1 diabetes.
Preconception care programs are as-
sociated with both reduced malforma-
tions and fewer early fetal losses in
pregnant women with type 1 diabetes
(12–14), perhaps due to improved glyce-
mic control in the first stages of preg-
nancy. It is possible that working with
women to improve metabolic control and
optimize their insulin regimen before
pregnancy might also help to reduce the
high rate of severe episodes of hypoglyce-
mia postconception, but this has yet to be
demonstrated.
We recently completed a random-
ized, open-label, parallel-group, multina-
tional, multicenter study investigating
maternal and fetal outcomes in 322
women with type 1 diabetes treated with
either prandial insulin aspart (IAsp) or
human insulin (15–17). IAsp injected im-
mediately before eating was as effective
and well tolerated as human insulin ad-
ministered 30 min before eating. Al-
though the study was somewhat
underpowered, there were strong trends
toward improved postprandial glucose
control and prevention of severe hypogly-
cemia in the IAsp group (15,16). This
study supports the conclusions of trials in
nonpregnant individuals with type 1 dia-
betes, which suggest that the advantages
of rapid-acting insulin analogs are most
likely to be seen in those with tight con-
trol (18–20).
The aim of this exploratory analysis
was to compare the incidence of severe
hypoglycemia during pregnancy between
women enrolled into the trial either pre-
conception or early in the first trimester.
Finally, we also compared the effects of
the different insulins on rates of severe
hypoglycemia according to the time of
enrollment of (pregnant) women into
the study.
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
From the 1Northern General Hospital, Sheffield, U.K.; the 2Rigshospitalet, University of Copenhagen,
Copenhagen, Denmark; 3Novo Nordisk, Soeborg, Denmark; the 4Helsinki University Central Hospital,
Helsinki, Finland; the 5Rabin Medical Center, Tel-Aviv University, Petah-Tiqva, Israel; the 6University of
Seville, Seville, Spain; and the 7Royal Victoria Hospital, Belfast, U.K.
Corresponding author: Simon Heller, s.heller@sheffield.ac.uk.
Received 27 August 2009 and accepted 17 November 2009. Published ahead of print at http://care.
diabetesjournals.org on 10 December 2009. DOI: 10.2337/dc09-1605.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
C l i n i c a l C a r e / E d u c a t i o n / N u t r i t i o n / P s y c h o s o c i a l R e s e a r c h
O R I G I N A L A R T I C L E
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 473
RESEARCH DESIGN AND
METHODS— A total of 322 women
with type 1 diabetes participated in this
open-label, randomized, parallel-group,
multinational, multicenter study con-
ducted at 63 sites in 18 countries (15–
17). The study was performed in
accordance with the Declaration of Hel-
sinki and was approved by the respective
ethics committees and health authorities
according to local regulations. Written in-
formed consent was obtained from sub-
jects before commencement of the study.
Eligible subjects were aged 18 years,
had insulin-treated type 1 diabetes for
12 months, and were either planning to
become pregnant or were already preg-
nant with a singleton pregnancy (gesta-
tional age 10 weeks). A1C was 8% at
confirmation of pregnancy. Subjects were
randomly assigned (1:1) to mealtime IAsp
(NovoRapid 100 IU/ml Penfill; Novo
Nordisk) injected immediately before
each meal or human insulin (human sol-
uble insulin, Actrapid 100 IU/ml, 3 ml
Penfill; Novo Nordisk) injected 30 min
before each meal, in combination with
NPH insulin (human isophane insulin,
100 IU/ml, 3 ml Penfill; Novo Nordisk)
one to four times per day.
In this exploratory analysis, the in-
tent-to-treat pregnant population in-
cluded all randomly assigned subjects
who were exposed to the trial drug and in
whom pregnancy was confirmed at some
point during the trial. This population
consisted of 99 subjects randomly as-
signed before known pregnancy (44 to
IAsp and 55 to human insulin) and 223
subjects randomly assigned in early preg-
nancy (113 to IAsp and 110 to human
insulin).
Severe hypoglycemia was defined as
an event requiring third-party assistance
associated with plasma glucose 3.1
mmol/l and/or reversal of symptoms after
food, glucagon, or intravenous glucose.
Nocturnal hypoglycemia was defined as
episodes occurring between midnight
and 0600 h. Hypoglycemia was recorded
prospectively preconception (where pos-
sible), during the first half of pregnancy
(20 weeks’ gestation), during the sec-
ond half of pregnancy (20 weeks’ gesta-
tion), and postpartum. Subjects were
followed throughout pregnancy with one
visit per trimester and at 6 weeks postpar-
tum. Hypoglycemic coma, glycemic con-
trol, duration of diabetes, and pretrial
insulin regimen (use of analogs) were also
recorded. Between study visits, the
women received routine diabetes and ob-
stetric care according to local practice.
Statistical analyses
The primary end point in this study was
severe hypoglycemia. Assuming an inci-
dence of one severe hypoglycemic epi-
sode during pregnancy with 7 months of
insulin treatment (21), 305 subjects were
required to complete the trial to detect a
treatment difference of 40% with a power
of 80% (5% significance level). Assuming
a dropout rate of 20%, 380 subjects
were to be randomly assigned.
In this analysis, rates of severe hypo-
glycemia were compared between those
women randomly assigned preconcep-
tion with those randomly assigned in
early pregnancy and between treatment
groups. Relative risk (RR) of severe hypo-
glycemia was estimated using a gamma
frailty model with treatment as a factor.
For women already pregnant at screen-
ing, delayed entry was used to account for
the different observation periods. A Cox
regression model accounted for recurrent
aspects of episodes. Incidence of noctur-
nal severe hypoglycemia is presented here
using descriptive statistics, as there were
too few events for formal analysis. The
observed rate is defined as number of
episodes per patient per year. The rela-
tionship between history of severe hypo-
glycemia and episodes during pregnancy
is based on subjects who had at least 30
days’ preconception exposure to the trial
drug, i.e., only those enrolled before
pregnancy.
RESULTS
Baseline patient demographics
The study includes the 99 of the 189 sub-
jects making up the preconception group
who became pregnant during the 12
months specified in the original protocol
(15). Age, A1C, BMI, and duration of di-
abetes were similar in subjects randomly
assigned preconception or in early preg-
nancy and between treatment groups
(Table 1).
Hypoglycemia in those randomly
assigned preconception versus those
randomly assigned in early
pregnancy
Overall, 23% of subjects (n 73) experi-
enced at least one episode of severe hypo-
glycemia during the study, and many
subjects experienced several episodes, in-
cluding six subjects who experienced
10 episodes. Rates of severe hypoglyce-
mia calculated for each week of preg-
nancy and postpartum are shown in Fig.
1A and B and are combined into rates in
early pregnancy, late pregnancy, and
postpartum in Fig. 1C. These rates appear
to peak in early pregnancy, with low val-
ues in the second half of pregnancy except
for a rise immediately before birth. Rates
of severe hypoglycemia in the first and
second halves of pregnancy are presented
separately here. Rates of severe hypogly-
cemia in subjects randomly assigned pre-
conception or early in pregnancy,
respectively, were 1.7 versus 3.4 events
per patient per year in the first half of
pregnancy, 0.8 versus 0.9 events per pa-
Table 1—Patient baseline demographics
IAsp  NPH Human insulin  NPH
Randomly
assigned
preconception
Randomly
assigned in
early pregnancy
Randomly
assigned
preconception
Randomly
assigned in
early pregnancy
n 44 113 55 110
Age (years) 28.6  3.7 29.2  5.1 28.8  4.3 29.2  4.7
A1C (%)* 7.3  1.0 6.8  0.7 7.1  1.2 6.8  0.8
BMI (kg/m2) 24.1  3.6 25.2  4.2 25.0  4.0 24.4  3.6
Duration of diabetes (years) 11.8  6.4 12.4  7.4 11.3  6.7 12.0  7.8
Pretrial insulin including
insulin analogs 24 (54.5) 49 (43.3) 30 (54.5) 50 (45.5)
Dose (IU  kg1  24 h1) 0.79  0.25 0.77  0.27 0.75  0.21 0.77  0.27
Preconception exposure to
trial drug (days) 153.8  108.2 NA 110.3  92.0 NA
Data are means SD or n (%). *A1C is from early pregnancy: at randomization in those randomly assigned
in early pregnancy and at pregnancy confirmation in those randomly assigned preconception. NA, not
applicable.
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tient per year in the second half of preg-
nancy, and 1.5 versus 2.1 events per
patient per year in the postpartum period
(Fig. 1C).
In the first half of pregnancy, the es-
timated risk of severe hypoglycemia was
70% higher in subjects randomly as-
signed in early pregnancy versus those
randomly assigned preconception (RR
1.70 [95% CI 0.91–3.18], P 0.097); in
the second half of pregnancy the RR was
1.35 (0.38–4.77) (P 0.640). Observed
rates for severe nocturnal hypoglycemia
in subjects randomly assigned precon-
ception versus postconception were 0.7
versus 0.9 events per patient per year, re-
spectively, in the first half of pregnancy;
0.4 versus 0.2 events per patient per year
in the second half of pregnancy; and 0.5
events per patient per year versus 0.6
postpartum.
Hypoglycemia in subjects treated
with IAsp and those treated with
human insulin
Subjects randomly assigned preconcep-
tion had consistently lower observed rates
of severe hypoglycemia with IAsp versus
human insulin, respectively, preconcep-
tion (0.9 vs. 2.4 events per patient per
year), in the first half of pregnancy (0.9 vs.
2.4 events per patient per year), in the
second half of pregnancy (0.3 vs. 1.2
events per patient per year), and postpar-
tum (0.2 vs. 2.2 events per patient per
year, NS for all) (Fig. 2). In subjects ran-
domly assigned preconception, the esti-
mated risk for severe hypoglycemia
during the first and second halves of preg-
nancy tended to be lower with IAsp than
with human insulin (RR 0.37 [95% CI
0.10–1.32], P  0.13 vs. 0.20 [0.02–
1.85], P  0.16, respectively). Estimated
risk with IAsp was 66% lower for the pre-
conception period (0.34 [0.07–1.71],
P  0.19 [NS]) and 92% lower postpar-
tum (0.08 [0.01–0.84], P 0.04) (Fig. 2).
Observed rates of severe nocturnal
hypoglycemia in subjects treated with
IAsp preconception were likewise consis-
tently lower than those for human insu-
lin–treated subjects preconception (0.3
vs. 1.5 events per patient per year), during
the first half of pregnancy (0.1 vs. 1.2
events per patient per year), during the
second half of pregnancy (0.1 vs. 0.7
events per patient per year), and postpar-
tum (0.2 vs. 0.7 events per patient per
year), respectively. The numbers in this
group were too small for a meaningful
analysis of statistical significance. In
subjects randomly assigned in early
pregnancy, rates of severe nocturnal hy-
poglycemia were similar for the IAsp and
human insulin treatment groups during
the first half of pregnancy (0.7 vs. 1.0
events per patient per year), the second
half of pregnancy (0.2 vs. 0.2 events per
patient per year), and postpartum (0.6
vs. 0.6 events per patient per year),
respectively.
Rates of hypoglycemia were higher in
subjects randomly assigned in early preg-
nancy to an insulin regimen differing
from their previous treatment. In subjects
who changed insulin regimens and were
randomly assigned to IAsp, the hypogly-
cemia rate was 3.0 versus 2.1 events per
patient per year for subjects who did not
change regimens. The same values for
those randomly assigned to human insu-
lin in early pregnancy were 4.5 events per
patient per year for subjects who changed
regimens versus 3.3 events per patient per
year for those already treated with human
insulin.
History of severe hypoglycemia
Of subjects reporting episodes of severe
hypoglycemia preconception (during the
trial), 67% (10 of 15) had severe hypogly-
cemia during pregnancy versus only 9%
(6 of 67) of subjects with no preconcep-
tion episodes.
Hypoglycemic coma
Eight episodes of hypoglycemic coma
were observed during pregnancy in this
study (three episodes with IAsp and five
episodes with human insulin), all in
Figure 1—Rate of severe hypoglycemia in pregnancy, grouped according to timing of random-
ization in the first half of pregnancy (A), in the second half of pregnancy and postpartum (B), and
in the first and second half of pregnancy and postpartum (C).
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subjects randomly assigned in early
pregnancy.
Glycemic control
During pregnancy, mean A1C and aver-
age plasma glucose levels were compara-
ble between treatment groups throughout
the study (Table 2). Plasma glucose was
derived as the average of the 8-point pro-
file for each subject. Profiles were taken
on a normal weekday within the week be-
fore the visit and included values pre-
meal, 90-min postmeal, at bedtime, and
at 0200 h.
CONCLUSIONS— This exploratory
analysis was based on data obtained from
the largest randomized controlled trial to
date involving an insulin analog in the
treatment of pregnant women with type 1
diabetes. Despite the limitations imposed
by the observational design, we believe
that exploring the influence of the timing
of entry into the trial on risk of hypogly-
cemia is clinically relevant. The data sug-
gest that women enrolled in a clinical trial
preconception experience fewer hypogly-
cemic episodes than those enrolled
postconception. Although the RRs in
women randomly assigned preconcep-
tion are not statistically significant be-
cause of a lack of power, the marked trend
to lower rates in this group is of interest.
It is well known that severe hypogly-
cemia is common during pregnancy and
is most likely to occur during the first tri-
mester (3,4). One observation from our
data is that the incidence of severe hypo-
glycemia does not peak in early preg-
nancy in women who were enrolled
preconception. This group had a low rate
of severe hypoglycemic episodes compa-
rable to the 1.3 events per patient per year
seen in the nonpregnant background
population (22).
It is possible that patients who en-
tered the trial preconception were more
motivated and experienced in diabetes
self-management than those enrolling
postconception, as represented by tighter
control and less hypoglycemia. However,
glycemic control (A1C and plasma glu-
cose) was similar between those ran-
domly assigned in early pregnancy and
those randomly assigned preconception.
An alternative explanation is that the extra
professional input in the preconception
period led to optimized insulin therapy
and a lower risk of hypoglycemia. Al-
though preconception counseling is asso-
ciated with a reduced malformation rate
in the offspring of women with type 1
diabetes (12–14), we are unaware of pre-
vious studies exploring the impact of pre-
conception input on severe hypoglycemia
during the ensuing pregnancy.
It is conceivable that subjects who
changed their insulin regimen may have
had higher rates of hypoglycemia than
those who did not change their insulin
regimen; however, the numbers of those
taking the same insulin in the trial were
too small to undertake formal compari-
sons. Nevertheless, switching to IAsp af-
ter human insulin treatment during
pregnancy did not seem to worsen the
risk of hypoglycemia, confirming the re-
sults of a smaller earlier study (23).
Our data show an apparent rise in hy-
poglycemia in the weeks immediately be-
fore birth. This finding might relate to a
fall in insulin requirements in the imme-
diate predelivery period. A further in-
triguing finding was that the benefit of a
rapid-acting insulin analog (IAsp) associ-
ated with a lower risk of severe hypogly-
cemia than that with human insulin (20)
tended to be most pronounced in women
who were randomly assigned preconcep-
tion. This result may be related to their
experience with the use of insulin IAsp
before the influence of the metabolic
changes of pregnancy. The rate of severe
hypoglycemia immediately postpartum
was considerably higher than that in the
last half of pregnancy and was also
higher than that seen in observational
data in nonpregnant diabetic popula-
tions (22), suggesting that women
should focus on reducing their postpar-
Figure 2—Observed rates of severe hypoglycemia in subjects randomly assigned preconception
(A) or early in pregnancy (B) treated with either IAsp or human insulin (HI).
Table 2—A1C and plasma glucose values
IAsp  NPH Human insulin  NPH
Randomly
assigned
preconception
Randomly
assigned in
early pregnancy
Randomly
assigned
preconception
Randomly
assigned in
early pregnancy
n 44 113 55 110
A1C (%)
First visit 7.3  1.0 6.8  0.7 7.1  1.2 6.8  0.8
First trimester visit 6.3  0.7 6.3  0.6 6.2  0.7 6.4  0.7
Second trimester
visit 6.0  0.7 5.9  0.7 6.0  0.6 5.9  0.7
Third trimester visit 6.2  0.5 6.0  0.7 6.2  0.5 6.1  0.7
Follow-up (6 weeks
postpartum) 6.6  0.7 6.5  0.9 6.6  0.8 6.4  0.8
Average plasma glucose
(mmol/l)
First visit 7.9  1.8 6.8  1.7 7.9  1.9 7.1  1.4
First trimester visit 7.1  1.6 6.6  1.4 6.7  1.7 6.6  1.3
Second trimester
visit 7.1  1.2 6.7  1.4 7.1  1.5 6.8  1.4
Third trimester visit 6.2  1.0 6.2  1.2 6.4  1.3 6.4  1.3
Data are means  SD.
Hypoglycemia and pregnancy in type 1 diabetes
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tum insulin dose and returning to pre-
conception glycemic control goals.
This analysis suggests that the initia-
tion of insulin analog treatment precon-
ception as opposed to during early
pregnancy results in a lower risk of severe
hypoglycemia in women with type 1 dia-
betes. The reasons for this finding remain
unclear but might include the influence of
preconception planning. Although the
limitations of exploratory analyses pre-
vent any firm conclusions, these data sug-
gest another potential advantage of
prenatal care that is worthy of further in-
vestigation. The observation should also
be taken into account in future clinical
trials during pregnancy in women with
type 1 diabetes.
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